A61K 38/2053
Il-8
Official title: {il-8}
A61K38/2053 (Il-8) appears on 98 US grants and 164 published applications in this corpus.
Search patents in A61K- Granted patents
- 98
- Published applications
- 164
- Assignees
- 85
- Inventors
- 263
- Latest grant
- 18 Nov 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 2 | 0 |
| 2000 | 3 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 2 |
| 2003 | 0 | 4 |
| 2004 | 1 | 6 |
| 2005 | 1 | 12 |
| 2006 | 2 | 11 |
| 2007 | 1 | 8 |
| 2008 | 1 | 2 |
| 2009 | 3 | 3 |
| 2010 | 2 | 7 |
| 2011 | 1 | 11 |
| 2012 | 5 | 6 |
| 2013 | 2 | 5 |
| 2014 | 8 | 13 |
| 2015 | 4 | 12 |
| 2016 | 10 | 9 |
| 2017 | 10 | 13 |
| 2018 | 8 | 4 |
| 2019 | 11 | 7 |
| 2020 | 2 | 6 |
| 2021 | 7 | 9 |
| 2022 | 6 | 3 |
| 2023 | 1 | 2 |
| 2024 | 1 | 5 |
| 2025 | 2 | 3 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy18 Nov 2025US 12,472,227 B2Rise Biopharmaceuticals Inc.
- Methods of conditioning patients for T cell therapy4 Nov 2025US 12,458,654 B2Kite Pharma, Inc.
- Precursory regulatory cytotrophoblast cells and uses thereof3 Sep 2024US 12,077,777 B2Accelerated Biosciences Corp.
- Processes for making and using a mesenchymal stem cell derived secretome23 May 2023US 11,654,160 B2Combangio, Inc.
- Methods of conditioning patients for T cell therapy8 Nov 2022US 11,491,187 B2Kite Pharma, Inc.
- Cxcl8 inhibitors for use in the treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid30 Jul 2026US 2026/0216292 A1Dompé Farmaceutici S.P.A.
- Methods of conditioning patients for t cell therapy4 Dec 2025US 2025/0367221 A1Kite Pharma, Inc.
- Processes for making and using a mesenchyme stem cell secretome for limbal stem cell deficiency (lscd) treatment10 Jul 2025US 2025/0222035 A1Combangio, Inc.
- Novel therapeutic comprising a secretome from mesenchymal stem cells of umbilicord tissue or wharton's jelly5 Jun 2025US 2025/0177455 A1Celligenics Pte. Ltd.
- Precursory regulatory cytotrophoblast cells and uses thereof5 Dec 2024US 2024/0400982 A1Accelerated Biosciences Corp.
Most cited
By later US patents
- Treatment of retinitis pigmentosa with human umbilical cord cells175US 7,413,734 B2Ethicon, Inc. · 2008
- Postpartum cells isolated from umbilical cord tissue, and methods of making and using the same84US 7,510,873 B2Ethicon, Inc. · 2009
- Soft tissue repair and regeneration using postpartum-derived cells76US 7,560,276 B2Ethicon, Inc. · 2009
- Regeneration and repair of neural tissue using postpartum-derived cells58US 7,524,489 B2Ethicon, Inc. · 2009
- Methods of conditioning patients for T cell therapy43US 9,855,298 B2Kite Pharma, Inc. · 2018